Could a diabetes pill help slow Alzheimer's? new study aims to find out.
NCT ID NCT07200622
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether oral semaglutide, a drug used for diabetes, is safe and can slow Alzheimer's disease. Sixty people with mild Alzheimer's will take the drug for one year. Researchers will check for side effects and use brain scans to see if the drug protects brain cells.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2025
An estimate. Start dates often move.
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Capable of giving and capacity to give informed consent. 2. An individual who can act as a reliable study partner with regular contact 3. Diagnosis of Alzheimer's disease according to the revised NIA-AA criteria 4. Age from 50 years 5. Mini-Mental State Examination (MMSE) score of ≥18; likely complete all the assessments 6. Rosen Modified Hachinski Ischemic score ≤4 7. On stable medication for 2 months before the screening visit; on or off cholinesterase inhibitors 8. Fluency in English and evidence of adequate premorbid intellectual functioning 9. Likely to be able to participate in all scheduled evaluations and complete all required tests Exclusion Criteria: 1. Any contraindications to the use of oral semaglutide 2. Significant neurological disease other than AD that may affect cognition 3. MRI/CT showing unambiguous aetiological evidence of cerebrovascular disease with regard to their dementia or vascular dementia fulfilling NINCDSAIREN criteria 4. Current presence of a clinically significant major psychiatric disorder 5. Current clinically significant systemic illness that is likely to result in deterioration of the subject's condition or affect the subject's safety during the study 6. Myocardial infarction within the last 1 year 7. Other clinically significant abnormality on physical, neurological or laboratory examination that could compromise the study or be detrimental to the subject 8. History of alcohol or drug dependence within the last 2 years 9. Current use of narcotic medications which could affect cognition. Subjects on anticoagulants will be allowed, but will not have an arterial line inserted 10. Women of childbearing potential. Women who could become pregnant will be required to use adequate contraception throughout the trial. Please see appendix A for more information. All women of childbearing potential will take a pregnancy test before the PET scan. 11. Any contraindications to MRI scanning 12. Any historical evidence of pancreatitis or gallstones as proven by ultrasound or medical admission. 13. History of medullary thyroid cancer 14. Patients diagnosed with T2DM who are unwilling to change their treatment to semaglutide.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alzheimer disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a massive data registry crack the code of Parkinson's and related brain diseases?
- Can a gentle electric current calm the mind in Alzheimer's?
- Alzheimer's vaccine aims to clear amyloid before memory fades
- Blood, eye, and brain scans team up to spot Alzheimer's earlier
- Can a home device slow Alzheimer's? pilot study tests pulsed electromagnetic therapy
- Eye scans as a window to the body: study probes retinal imaging across diseases